Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
prednisone + interferon alfa-2b
- Development stage
- Unknown
- Lead developer
- Fundación PETHEMA
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
This maintenance therapy regimen consists of the synthetic glucocorticoid prednisone and the recombinant cytokine interferon alfa-2b. It was evaluated by the PETHEMA Foundation (Grupo Español de Mieloma) in the GEM 2000 Phase 3 clinical trial as a post-autologous stem cell transplantation strategy for patients with symptomatic multiple myeloma. Prednisone acts as an anti-inflammatory and lymphocytotoxic agent by binding to glucocorticoid receptors, while interferon alfa-2b exerts antiproliferative, immunomodulatory, and anti-angiogenic effects by binding to the Type I interferon receptor (IFNAR). The regimen was designed to prolong remission and improve survival outcomes in patients who achieved a response following induction chemotherapy and high-dose melphalan conditioning.
- Other names
- Prednisone and Interferon alfa-2b maintenance therapy
02
Targets
GR (Glucocorticoid receptor)IFNAR1 (Interferon alpha/beta receptor 1)IFNAR2 (Interferon alpha/beta receptor subunit 2)
Beyond the preview
Go deeper on prednisone + interferon alfa-2b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on prednisone + interferon alfa-2b.